

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney's Docket Number

047763-5017

U.S. Application No.

Unassigned

Priority Date Claimed

International Application. No.

International Filing Date

PCT/AU99/00285

April 16, 1999

April 16, 1998

Title of Invention

PRODUCTION OF FURANONES

Applicants For DO/EO/US

Roger READ and Naresh KUMAR

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
[] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
[] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).
[X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
[X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
a. [] is transmitted herewith (required only if not transmitted by the International Bureau).
b. [X] has been transmitted by the International Bureau.
c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).
[] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
[X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
b. [] have been transmitted by the International Bureau.
c. [] have not been made; however, the time limit for making such amendments has NOT expired.
d. [X] have not been made and will not be made.
[] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
[] An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
[] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

ns 11. to 14. below concern other document(s) or information included:

- [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
[] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
[X] A FIRST preliminary amendment.
[] A SECOND or SUBSEQUENT preliminary amendment.
[] Other items or information:
[X] [a]. WIPO publication WO 99/54323 first page including abstract and remaining pages including substitution sheets for page 2 of the description and pages 25-34 containing claims, which substitute sheets were submitted under Article 34, on December 12, 1999

41673305

Unassigned

PCT/AU99/00285

047763-5017

[X] The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO.....\$860.00

International preliminary examination fee paid to

USPTO (37 CFR 1.482).....\$690.00

No international preliminary examination fee paid to

USPTO (37 CFR 1.482) but international search fee
paid to USPTO (37 CFR 1.445(a)(2)).....\$710.00

Neither international preliminary examination fee

(37 CFR 1.482) nor international search fee

(37 CFR 1.445(a)(2)) paid to USPTO.....\$1000.00

International preliminary examination fee paid to USPTO

(37 CFR 1.482) and all claims satisfied provisions

of PCT Article 33(2)-(4).....\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 1000.00

Large of \$130.00 for furnishing the oath or declaration later than

[] 30 months from the earliest claimed priority date

[] 37 CFR 1.492(e)).

\$

as	Number Filed	Number Extra	Rate	
Claims	48 - 20 =	28	X \$18.00	\$ 504.00
Independent Claim	7 - 3 =	4	X \$80.00	\$ 320.00
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$

TOTAL OF ABOVE CALCULATIONS =

\$ 1824.00

or filing by 1/2 for filing by small entity, if applicable. Verified

Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

\$

SUBTOTAL =

\$ 1824.00

or recording the enclosed assignment (37 CFR 1.21(h)). The

[] 20 [] 30 months from the earliest claimed priority date

[] 37 CFR 1.492(f)).

+\$

TOTAL NATIONAL FEE =

\$ 1824.00

or recording the enclosed assignment (37 CFR 1.21(h)). The

Document must be accompanied by an appropriate cover sheet

[] 37 CFR 3.28, 3.31).

\$40.00 per page

+\$

TOTAL FEES ENCLOSED =

\$ 1824.00

Amount to be

refunded

\$

charged

\$

[X] A check in the amount of **\$1824.00** to cover the above fees is enclosed.[] Please charge my Deposit Account No. 50-0310 in the amount of \$-0-
to cover the above fees. A duplicate copy of this sheet is enclosed.[X] **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to
charge any additional fees during the entire pendency of this application including fees due under 37 CFR §1.16
and §1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Serial No. 009629

ALL CORRESPONDENCE TO:

a, Lewis & Bockius LLP

1 Street, N.W.

ington, D.C. 20036

67-7000

Elizabeth C. Weimar

Elizabeth C. Weimar

Reg. No. 44,478

Submitted: October 16, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Roger READ, et al.)	
)	
U.S. Application No.: To Be Assigned)	Group Art Unit: Unassigned
)	
Date of National)	
Stage Entry : October 16, 2000)	Examiner: Unassigned
)	
Based on PCT/AU99/00285)	
Filed : April 16, 1999)	
)	
For: PRODUCTION OF FURANONES)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above-identified application on the merits, please amend the application, without prejudice, as follows:

IN THE CLAIMS:

Please cancel claim 21.

Please amend claims 17, 18, 19, 20, 22, 23 and 24 as follows:

Claim 17, line 2, change "any one of claims 6 to 16" to -- claim 6--;

Claim 18, lines 12 and 13, change "arylalkyl," to --arylalkyl.-- and delete the remainder of the sentence;

Claim 19, line 2, change "compound of claim 18. " to --compound.--;

Claim 20, line 1, change “polymer is” to -- polymer comprises--; and,

line 2, change “one fimbrolide compound in accordance with claim 18” to -- one of said fimbrolide compounds--;

line 3, change “monomers” to --monomer--;

Claim 22, lines 2 and 3, change “claims 1 to 5 or 17” to --claim 1.-- and delete the remainder of the sentence;

Claim 23, lines 2 and 3, change “claims 1 to 5 or 17” --claim 1-- and delete the remainder of the sentence;

Claim 24, lines 1-3, after “compound” insert --in accordance with claim 1.-- and delete the remainder of the sentence.

Please add new claims 27 - 49 as follows:

- 27. A fimbrolide derivative produced by a method in accordance with claim 9.
- 28. A fimbrolide derivative produced by a method in accordance with claim 12.
- 29. A fimbrolide derivative produced by a method in accordance with claim 15.
- 30. A method of disinfection comprising the application of a compound in accordance

with claim 1 to any surface in an amount effective to act as an antimicrobial agent, an antiseptic, a microbial static agent, or an antifouling agent.

31. A method of disinfection comprising the application of a compound in accordance with claim 17 to any surface in an amount effective to act as an antimicrobial agent, an antiseptic, a microbial static agent, or an antifouling agent.

32. A method of disinfection comprising the application of a compound in accordance with claim 27 to any surface in an amount effective to act as an antimicrobial agent, an antiseptic, a microbial static agent, or an antifouling agent.

33. A method of disinfection comprising the application of a compound in accordance with claim 28 to any surface in an amount effective to act as an antimicrobial agent, an antiseptic, a microbial static agent, or an antifouling agent.

34. A method of disinfection comprising the application of a compound in accordance with claim 29 to any surface in an amount effective to act as an antimicrobial agent, an antiseptic, a microbial static agent, or an antifouling agent.

35. An antimicrobial, antiseptic and/or microbial static composition including at least one compound in accordance with claim 17.

36. An antimicrobial, antiseptic and/or microbial static composition including at least one oligomer or polymer in accordance with claim 18.

37. An antimicrobial, antiseptic and/or microbial static composition including at least one compound in accordance with claim 27.

38. An antimicrobial, antiseptic and/or microbial static composition including at least one compound in accordance with claim 28.

39. An antimicrobial, antiseptic and/or microbial static composition including at least one compound in accordance with claim 29.

40. An antifouling composition including at least one compound in accordance with claim 17.

41. An antifouling composition including at least one oligomer or polymer in accordance with claim 18.

42. An antifouling composition including at least one compound in accordance with claim 27.

43. An antifouling composition including at least one compound in accordance with claim 28.

44. An antifouling composition including at least one compound in accordance with claim 29.

45. A surface coating composition incorporating at least one compound in accordance with claim 17.

46. A surface coating composition incorporating at least one oligomer or polymer in accordance with claim 18.

47. A surface coating composition incorporating at least one compound in accordance with claim 27.

48. A surface coating composition incorporating at least one compound in accordance with claim 28.

49. A surface coating composition incorporating at least one compound in accordance with claim 29.--

REMARKS

The changes to the claims requested above have been made so as to eliminate multiple claim dependencies and to present claim language more conventional for practice in the United States. These changes do not introduce new matter, nor do they alter the subject matter presented and examined in the corresponding International Application.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: Elizabeth C. Weimar
Elizabeth C. Weimar
Reg. No. 44,478

Dated: October 16, 2000
MORGAN, LEWIS & BOCKIUS LLP
Intellectual Property Support Unit
1800 M Street, NW
Washington, DC 20036-5869
(202) 467-7000

Production of furanones

Technical Field

The present invention relates to the side chain functionalisation of fimbrolides (halogenated 3-alkyl-5-methylene-2(5*H*)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, and polymers.


Background Art

It is known that a variety of fimbrolides possessing antifungal and antimicrobial properties can be isolated from red marine algae *Delisea fibriata*, *Delisea elegans* and *Delisea pulchra*. The very few reported syntheses of functionalised fimbrolides use (E)- β -bromo- β -lithioacrylate or 3-formyl-6-methylfuran or allenes as starting materials. These syntheses are unnecessarily long, tedious and give very low yields of the fimbrolides. The present inventors have recently reported the preparation of a range of fimbrolides having different sized chain lengths (Manny et al (1997) Tetrahedron 53: 15813-15826, the disclosure of which is incorporated herein by reference).

Prior to the present invention, it had not been appreciated that the side chains of the fimbrolides could be functionalised directly affording a variety of halogen or oxygen functionalised fimbrolides. We have found that fimbrolides behave like allylic or benzylic compounds in their reactivity and consequently are amenable to free radical functionalisation. The derived halogen compounds can be converted to alcohols or to esters directly from the halogen derivatives or to ketones, esters, amides, alcohols or other halides indirectly from the corresponding esters or alcohols. The fimbrolides substituted with an appropriate group in the alkyl chain are capable of yielding polymers through that group, either directly or via copolymerisation with suitable monomers. It is the preparation of these fimbrolide-based halides, alcohols, esters, ethers, amines, amides, and nitro compounds, ketones, oligomers and polymers that form the major aspect of this invention.

The fimbrolides prepared in accordance with the present invention include not only synthetic versions of the two naturally occurring fimbrolides, but also other functionalised fimbrolides which we believe to be

novel compounds. The compounds synthesised in accordance with the present invention may be according to formula (I):



(I)

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH,

$OC(O)R_6$, = O, amine, azide, thiol, R_6 , mercaptoalkyl, alkenyloxy,

mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoaryllalkyl,

$SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and


R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl.

Compounds according to Formula (I), apart from those in which $R_1 = \text{propyl}$, $R_2 = \text{Br}$, $R_3 = \text{H}$, $R_9 = \text{Br}$ and Z is $OC(O)CH_3$ or OH, are believed to be novel and form part of the present invention.

In the structural formulae given herein, a particular geometry is not to be taken as specified unless specifically stated. For example, the formulae are intended to cover the both Z-isomers and E-isomers.

Disclosure of Invention

In a first aspect, the present invention provides a method to form a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):



(Ia)


wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl, whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen (X = F, Cl, Br or I), OH, OOH, OC(O)R₁ or =O);

R₂ and R₃ are independently or both hydrogen or halogen; and

R₉ is halogen.

The fimbrolide used in the method may be a fimbrolide having the formula:



wherein R₁, R₂, R₃ and R₉ are as defined above.

Preferably the halogenating agent is selected from N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, bromine, cupric bromide, and phenyltrimethylammonium perbromide. It will be appreciated, however, that other halogenating agents would also be suitable for the present invention.

Preferably the oxygenating agent is selected from lead tetraacetate, Rose Bengal/oxygen gas, hydrogen peroxide/vanadium pentoxide, selenium dioxide, and 3-chloroperoxybenzoic acid. It will be appreciated, however, that other oxygenating agents would also be suitable for the present invention.

The reaction conditions are selected so as to be appropriate to the nature of the reaction being undertaken. Preferably, the reaction conditions


when an halogenating agent is used are for example carbon tetrachloride or chloroform or dichloromethane/with or without light/reflux, tetrahydrofuran/room temperature.

Preferably, the reaction conditions when an oxygenating agent is used are acetic acid or acetic acid mixed with a solvent/reflux, pyridine/room temperature, acetone/30°C, dioxane/reflux, and dichloromethane/room temperature.

The present inventors have found that the preferred bromination conditions are N-bromosuccinimide in the presence of catalytic amounts of benzoyl peroxide in carbon tetrachloride and light/reflux. The source of light may be any suitable source for example, the present inventors have found that a 250 W sun lamp is quite suitable.

In a second aspect, the present invention consists in a fimbrolide derivative having formula (Ia), wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; X is a halogen (X = Cl, Br or I) or oxygen (X = OH, OOH, OC(O)R₁ or =O); R₂, R₃ are independently or both hydrogen or halogen and; R₄ is halogen, with the proviso that the following two derivatives are excluded R₁= propyl, X= OH, R₂= Br, R₃=H: and R₁= propyl, X= OC(O)CH₃, R₂= Br, R₃=H).

In a third aspect, the present invention consists of a method to form a fimbrolide derivative, the method including displacement and/or functionalisation of the halogen or oxygen substituent in the fimbrolide side chain by treating with a nucleophile or an electrophile to form compounds with formula (II):



(II)


wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl, whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen;

R₉ is halogen; and

R₄ is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, OC(O)R₁, SC(O)R₁, OS(O)R₁, OS(O)₂R₁, NHC(O)R₁, OC(O)NHR₁, or =O.

The fimbrolide treated in the method of the third aspect may be compound of the formula:



wherein R₁, R₂, R₃ and R₉ are as defined above and R₇ is halogen (F, Cl, Br or I), OH, OOH, OC(O)R₁ or =O);

Preferably the nucleophile is selected from metal halides, water, organic metal carboxylates, organic alcohols, dimethyl sulfoxide, and organonitriles. It will be appreciated, however, that other nucleophiles would also be suitable for the present invention.

Preferably the electrophile is selected from organic acids, isocyanates, carboxylic or sulfonic acid halides or active acylating or sulfinylating agents such as carbonyl imidazoles, carboxylic anhydrides, carbodiimide activated carboxylic acids, sulfonyl halides, and sulfonic anhydrides and diethylaminosulfur trifluoride. It will be appreciated, however, that other electrophiles would also be suitable for the present invention.


The reaction conditions of the method of the third aspect are selected to be appropriate to the nature of the reaction being undertaken.

The reaction conditions suitable when using a nucleophile are acetone or dioxane/room temperature or reflux, water/dioxane or acetone or tetrahydrofuran/reflux, metal acetates/organic acids/neat or high boiling solvents/reflux, organic alcohols/reflux, dimethyl sulfoxide/room temperature, and organonitriles/acid catalyst or silver triflate/reflux.

The reaction conditions suitable when using an electrophile are organic acids/neat and/or solvent/acid catalyst/reflux, organic acid halides or anhydrides or isocyanates /base catalyst/solvent/room temperature, and diethylaminosulfur trifluoride/dichloromethane/low temperature.

In a fourth aspect the present invention consists in a fimbrolide derivative having formula (II), wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; R_2 and R_3 are independently or both hydrogen or halogen; R_9 is halogen, and R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$, with the proviso that the following two derivatives are excluded $R_1 = \text{propyl}$, $X = OH$, $R_2 = Br$, $R_3 = H$; 2. $R_1 = \text{propyl}$, $X = OC(O)CH_3$, $R_2 = Br$, $R_3 = H$.

In a fifth aspect, the present invention consists of a method to form a fimbrolide derivative the method including reacting an hydroxyl substituent in the fimbrolide side chain with an oxidising agent to form a compound in accordance with formula (III):



(III)


wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;

R_9 is halogen; and

R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

The hydroxyl substituted fimbrolide used in the method of the fifth aspect may have the formula:



wherein R_5 , R_2 and R_3 are as defined above.

Preferably, the oxidising agents are acidic chromium reagents in any form either free or polymer supported (e.g. Jones reagent, pyridinium chlorochromate, pyridinium dichromate, chromium trioxide *etc*), manganese dioxide, potassium permanganate, selenium dioxide, ceric ammonium nitrate, ruthenium tetroxide, and hot nitric acid. It will be appreciated, however, that other oxidation agents may also be used for the present invention.


The reaction condition under which the method of the third aspect is performed may be any suitable conditions. The reaction conditions preferably use Jones reagent/with or without phase transfer catalysts/acetone/room temperature, toluene/reflux, potassium permanganate/buffered solution/room temperature, dioxane/reflux, ceric ammonium nitrate/ aqueous acetic acid/steam bath, carbon tetrachloride/reflux, and acetic acid/steam bath. It will be appreciated, however, that other reaction conditions may also be used for the present invention.

The present inventors have found that the use of Jones reagent in acetone/room temperature is particularly suitable.


In a sixth aspect, the present invention consists in a fimbrolide derivative having the formula (III) wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; R_2 and R_3 are independently or both hydrogen or halogen; R_9 is halogen; and R_5 is OH or the same as R_1 .

The present invention also provides a method for forming fimbrolide oximes, imines, hydrazones and amines.

Accordingly in a seventh aspect, the present invention consists of a method to form a fimbrolide analogue derived from a compound of formula (III), the method including reacting an aldehyde or ketone substituent in the fimbrolide side chain of the compound with an amine derivative to form a compound with formula (IV) or (V):



(IV)



(V)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen;

R₉ is halogen and

R₈ is OH, NHR₁, NHC(X)NH₂, NHC(X)NHR₁ (X=O, S, NR₁) or any R₁.

Preferably, the amine derivatives used are hydroxyl amine hydrochloride, alkyl and aryl hydrazines, alkyl or aryl amine in the presence or absence of a reducing agent. It will be appreciated, however, that other amine derivatives may also be used for the present invention.

The reaction conditions used in the method of the seventh aspect may be any conditions suitable for the nature of the reaction carried out. For example when using an amine derivative suitable conditions are ethanol or methanol/room temperature or reflux, toluene in the presence of a catalyst/room temperature or reflux and ethanol or methanol in the presence of sodium borohydride or sodium cyanoborohydride/room temperature or reflux.

In a eighth aspect, the present invention consists in a fimbrolide derivative having the formula (IV) and (V) wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or

fluorophilic: R_2 and R_3 are independently or both hydrogen or halogen, R_9 is halogen and R_8 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .

In a ninth aspect the present invention provides an oligomer or polymer formed by oligomerising or polymerising a compound in accordance with the present invention directly or with one or more other monomers.


The one or more other monomer may be any suitable polymerisable copolymer eg acrylate ester such as alkyl, hydroxyalkyl, aminoalkyl, or substituted aryl, acrylates or methacrylates, crotonates, substituted or unsubstituted acrylonitriles, vinyl alcohols or acetates, and styrene.

In a tenth aspect, the present invention consists in incorporation of fimbrolides according to the first, third, fifth or seventh aspects of the present invention either in surface coatings or polymers through the newly introduced functionality on the alkyl chain or the alkyl chain itself via direct polymerisation or copolymerisation with suitable monomers.

In a eleventh aspect, the present invention consists in a fimbrolide derivative produced by the method according to the first, third, fifth or seventh aspects of the present invention.

In an twelfth aspect, the present invention consists in the use of a fimbrolide derivative according to the present invention. The present inventors have found that many of the fimbrolide derivatives having the formula (I), have antimicrobial, antiseptic, microbacterial static and/or antifouling properties. Accordingly, the fimbrolide derivatives are suitable for use as antimicrobial and/or antifouling agents.

In a thirteenth aspect the present invention provides a compound of formula (VI):



(VI)

wherein R_2 , R_3 , R_9 and R_1 (except where R_1 is hydrogen) are as defined above.

An example of a compound in accordance with this form of the invention is 4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone.

The compound of the thirteenth aspect may be formed by dehydrating hydroxyl substituent in the fimbrolide side chain. The dehydration may be catalysed by H₂SO₄ in the presence of toluene.

As used herein and in the claims:

The term "halogen" means F, Cl, Br, or I.

The term "alkyl" is taken to mean straight chain, branched chain and cyclic alkyl or cycloalkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, and the like. Preferably the alkyl group is of 1-25 carbon atoms. The alkyl group may be optionally substituted by one or more of fluorine, chlorine, bromine, iodine, carboxyl, C1-C4-alkoxycarbonyl, hydroxyl, carbonyl and aryl groups.

The term "aryl" is taken to include substituted and unsubstituted phenyl, naphthyl or other benzenoid aromatic or any aromatic heterocyclic nucleus containing N, O, S, P or chalcogen heteroatom such as pyridyl, pyrimidyl, indolyl or furanyl.

The term "alkoxy" as used herein and in the claims denotes straight chain or branched alkoxy, preferably containing 1 to 25 carbon atoms and like functional groups, such as polyethylene glycol (PEG) and cyclic ethers.

The term "alkenyl" is taken to mean a straight chain, a branched chain or cycloalkyl group having one or more double bonds. Preferably the alkyl group is 1-25 carbon atoms. The alkyl group may optionally be substituted by one or more halogen atoms, carbonyl, hydroxyl, carboxyl, C1-C4-alkoxycarbonyl groups.

The term "amine" as used herein and in the claim means any basic primary, secondary or tertiary nitrogen containing group or molecule, aromatic or non-aromatic.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or step, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and accompanying drawings.

Brief Description of Drawings

Figure 1 shows the structure of *Delisea pulchra* furanones and synthetic analogues and derivatives tested in barnacle settlement assay.

Figure 2 shows the effect of furanones 2, 281, 2223, 2425, 26, 27, and 28 on the settlement of barnacle cyprid larvae as measured by settlement expressed as a percent of the control.

Figure 3 shows growth curves of *Staphylococcus aureus* against different furanones.

Figure 4 shows growth curves of *Staphylococcus aureus* against compounds 33/34 and 45.

Figures 5 -5I show the structural formulae for other specific examples of compounds in accordance with the present invention.

Modes for Carrying Out the Invention

EXPERIMENTAL DETAILS

Fimbricide Production

General. Melting points are uncorrected. Microanalyses were performed by Dr H.P. Pham of The University of New South Wales Microanalytical Laboratory. ¹H NMR spectra were obtained in CDCl₃ on a Bruker AC300F (300 MHz) or a Bruker DMX500 (500 MHz) spectrometer. ¹³C NMR were obtained in the same solvent on a Bruker AC300F (75.5 MHz) or a Bruker DMX500 (125.8 MHz) spectrometer. Chemical shifts were measured on the δ scale internally referenced to the solvent peaks: CDCl₃ (d 7.26, d 77.04). Ultraviolet spectra were measured on an Hitachi U-3200 spectrophotometer and refer to solutions in absolute MeOH. Infrared spectra were recorded on a Perkin-Elmer 298 or a Perkin-Elmer 580B spectrophotometer and refer to paraffin mulls. The electron impact mass spectra were recorded on a VG Quattro mass spectrometer at 70eV ionisation

voltage and 200°C ion source temperature. FAB spectra were recorded on an AutoSpecQ mass spectrometer. Column chromatography was carried out using Merck silica gel 60H (Art. 7736), whilst preparative thin layer chromatography was performed on 2 mm plates using Merck silica gel 60GF₂₅₄ (Art. 7730).

RESULTS

Fimbroside Production

Examples of a number of fimbroside produced are provided below.

EXAMPLE 1

4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

N-bromosuccinimide (17.3 g, 0.097 mol) was added to a solution of 4-bromo-5-(bromomethylene)- and/or 5-(dibromomethylene)-3-ethyl-2(3H)-furanone (22.6 g, 0.08 mol) in carbon tetrachloride (500 ml) containing benzoyl peroxide (0.25 g). The mixture was irradiated with a 250 W lamp and refluxed in an oil bath for 18h. After cooling the mixture to room temperature it was filtered and the precipitate washed with carbon tetrachloride (50 ml). The filtrate was evaporated under reduced pressure and the crude product was purified by silica gel chromatography using dichloromethane / light petroleum (2 : 3) as the eluent to yield the bromo compounds (22.0 g, 76%) as a 4 : 1 mixture.

4-Bromo-5-(bromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

A pale yellow solid, m.p. 79°C. ν_{\max} 2850, 1750, 1630, 1580, 1440, 1360, 1270, 1180, 1065, 1000, 970, 940, 1080, 755 cm^{-1} . λ_{\max} 306 nm (e 10826). ^1H n.m.r. δ (CDCl_3) 2.06, d, J 7.2 Hz, (H2')₃; 5.00, q, J 7.2 Hz, H1'; 6.45, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 22.3, C2'; 35.7, C1'; 94.3, 5-CHBr; 130.5, C4; 133.7, C; 149.5, C5; 165.8, C2. Mass spectrum: m/z 364 (M ($^{81}\text{Br}_3$), 2%); 362 (M ($^{81}\text{Br}_2$, ^{79}Br), 8); 360 (M (^{81}Br , $^{79}\text{Br}_2$), 8); 358 (M ($^{79}\text{Br}_3$), 2); 283 (85); 281 (100); 279 (85); 202 (12); 200 (12); 173 (18); 158 (35); 156 (35); 145 (38); 143 (42); 133 (28); 121 (26).

5-(Dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

A white solid m.p. 119°C. ν_{\max} 2900, 1720, 1590, 1450, 1370, 1250, 1170, 1080, 1060, 1000, 960, 840, 770, 720 cm^{-1} . λ_{\max} 319 nm (e 12225). ^1H n.m.r. δ (CDCl_3): 1.99, t, J 7.2Hz, (H2')₃; 4.87, q, J 7.2 Hz, H1'; 7.56, s, H4. ^{13}C n.m.r. δ (CDCl_3): 23.9, C2'; 36.0, C1'; 82.8, (5-CBr₂); 134.7, C4; 138.2, C3; 149., C5; 165.5, C2. Mass spectrum: m/z 364 (M ($^{81}\text{Br}_3$), 9%); 362 (M ($^{81}\text{Br}_2$,

^{79}Br). 18); 360 (M (^{81}Br $^{79}\text{Br}_2$), 18); 358 (M ($^{79}\text{Br}_3$), 9); 283 (78); 281 (100); 279 (78); 227 (8); 225 (12); 223 (8); 202 (22); 200 (32); 174 (18); 172 (44); 146 (42); 145 (50); 144 (50); 143 (60).

EXAMPLE 2

3-(1-Bromobutyl)-5-(dibromomethylene)-2(5H)-furanone

The procedure described for 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromomethyl)-2(5H)-furanone was used to treat 3-butyl-5-(dibromomethylene)-2(5H)-furanone (4.95 g, 16 mmol) with N-bromosuccinimide (3.83 g, 22 mmol) in carbon tetrachloride (70 ml) to give after chromatography the bromobutyl furanone as a yellow solid (5.48 g, 88%) m.p. 55°C. ν_{max} 3087, 2924, 2854, 1778, 1463, 1377, 967, 832 cm^{-1} . λ_{max} 314.2 nm (e 28115). ^1H NMR d: 0.99 t, 3H, H-4'; 1.50 m, 2H, H-3'; 2.10 m, 2H, H-2'; 4.72 t, 1H, H-1'; 7.54 s, 1H, H4. Mass spectrum: m/z 392 (M+1($^{81}\text{Br}_3$); 389(M+1(^{81}Br , $^{79}\text{Br}_2$); 386(M+1($^{79}\text{Br}_3$); 311; 309; 307; 269; 267 (100%); 265.

EXAMPLE 3

4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)- 3-(1-acetoxybutyl)-2(5H)-furanone

A solution of 4-bromo-5-(bromomethylene)- and/or 5-(dibromomethylene)- 3-(1-bromobutyl)-2(5H)-furanone (3.00 g, 7.7 mmol) in glacial acetic acid (160 ml) containing sodium acetate (1.20 g, 15 mmol) was refluxed for 18h. The mixture was concentrated to approximately 20 ml and neutralised with excess saturated sodium carbonate solution. The residual oil was extracted with ether (3 x 100 ml), washed with brine, dried over sodium sulfate and evaporated. The crude product was chromatographed on silica gel using dichloromethane / light petroleum (1 : 1) as eluent to yield the acetoxybutylfuranones (0.96 g, 34%) as a 4 : 1 mixture.

4-Bromo-5-(bromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone

A pale yellow oil ν_{max} 2940, 1775, 1740, 1640, 1600, 1450, 1420, 1370, 1220, 1100, 1020, 985, 760, 730 cm^{-1} . λ_{max} 295 nm (e 6265). ^1H n.m.r. δ (CDCl_3) 0.93, t, J 7.2 Hz, (H4')₃; 1.35, m, (H3')₂; 1.84, m, (H2')₂; 2.07, s, COCH_3 ; 5.50, bt, J 7.2 Hz, H1'; 6.37, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.5, C4'; 18.5, COCH_3 ; 20.6, C3'; 33.7, C2'; 68.2, C1'; 93.5, 5-CHBr; 130.2, C4; 131.4, C3; 149.7, C5; 164.2, C2; 170.2, CO. Mass spectrum: m/z 370, (M ($^{81}\text{Br}_2$), <5%); 368 (M (^{81}Br , ^{79}Br), <5); 366, (M ($^{79}\text{Br}_2$), <5); 327 (18); 325

(26): 323 (18); 289 (22); 287 (22); 285 (14); 283 (28); 281 (14); 247 (12); 245 (12); 229 (14); 227 (14); 149 (28).

5-(Dibromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone

A pale yellow solid mp 76°C. ν_{\max} 2880, 1760, 1735, 1445, 1370, 1225, 1170, 1100, 1030, 950, 840, 765, 7320 cm^{-1} . λ_{\max} 314 nm (e 8900). ^1H n.m.r. δ (CDCl_3) 0.94, t, J 7.2 Hz, (H_4')₃; 1.36, m, (H_3')₂; 1.84, m, (H_2')₂; 2.12, s, COCH_3 ; 5.59, bt, J 6.2 Hz, H_1' ; 7.39, bs, H_4 . ^{13}C n.m.r. δ (CDCl_3): 13.6, C_4' ; 18.3, COCH_3 ; 20.9, C_3' ; 34.8, C_2' ; 68.3, C_1' ; 81.6, 5-CBr₂; 135.0, C_4 ; 136.1, C_3 ; 149.3, C_5 ; 166.1, C_2 ; 169.9, CO. Mass spectrum: m/z 370, (M ($^{81}\text{Br}_2$), 28%); 368 (M (^{81}Br , ^{79}Br), 54); 366, (M ($^{79}\text{Br}_2$), 28); 328 (20); 327 (18); 326 (36); 325 (28); 324 (20); 323 (18); 289 (16); 287 (16); 247 (16); 245 (16); 229 (12); 227 (12); 198 (10).

EXAMPLE 4

5-(Dibromomethylene)-3-(1-acetoxyethyl)-2(5H)-furanone

The procedure described for 4-bromo-5-(bromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone was used to treat 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (2.80 g, 7.7 mmol) with sodium acetate (1.20 g, 15 mmol) in glacial acetic acid (160 ml) to give after chromatography the acetoxyethyl furanone as a white solid (0.88 g, 34%) m.p. 124°C. ν_{\max} 2880, 1750, 1610, 1445, 1365, 1230, 1170, 1080, 1030, 990, 960, 930, 835, 760, 715 cm^{-1} . λ_{\max} 313 nm (e 31296). ^1H n.m.r. δ (CDCl_3) 1.53, d, J 6.2 Hz, (H_2')₃; 2.13, s, COCH_3 ; 5.66, m, 1H, H_1' ; 7.43, bs, H_4 . ^{13}C n.m.r. δ (CDCl_3): 18.9, CH_3 ; 20.9, C_2' ; 53.4, C_1' ; 81.7, 5-CHBr; 134.6, C_4 ; 136.7, C_3 ; 149.2, C_5 ; 166.0, C_2 ; 169.6, CO. Mass spectrum: m/z 342, (M ($^{81}\text{Br}_2$), <5%); 340 (M (^{81}Br , ^{79}Br), 6); 338, (M ($^{79}\text{Br}_2$), <5); 300 (30); 299 (26); 298 (62); 297 (44); 296 (32); 295 (22); 281 (22); 279 (18); 261 (34); 259 (37); 219 (68); 217 (70); 201 (32); 200 (31); 199 (34); 174 (20); 172 (30); 170 (14); 157 (22); 145 (28); 143 (24).

EXAMPLE 5

5-(Dibromomethylene)-3-(1-thioacetoxyethyl)-2(5H)-furanone

A solution of 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (3.00 g, 7.7 mmol) in glacial acetic acid (160 ml) containing potassium thioacetate (1.20 g, 15 mmol) was refluxed for 12h. The mixture was concentrated to approximately 20 ml and neutralised with excess saturated sodium carbonate solution. The residual oil was extracted with ether (3 x 100 ml), washed with brine, dried over sodium sulfate and evaporated. The crude product was chromatographed on silica gel using dichloromethane /

light petroleum (1 : 1) as eluent to yield the thioacetoxyethylfuranones (0.96 g, 34%) as a yellow oil ν_{\max} 3200, 2910, 2850, 1780, 1730, 1690, 1600, 1450, 1420, 1380, 1350, 1270, 1170, 1105, 1010, 960, 880, 850, 810, 770 cm^{-1} . λ_{\max} 297 nm (e 6664). ^1H NMR d: 1.61 (d, 3H, J 7.2 Hz, H-2'); 2.52 (s, 3H, SCoCH_3); 4.49 (q, 1H, J 7.2 Hz, H-1'); 7.44 (s, 1H, H4). Mass spectrum: m/z 358 (M ($^{81}\text{Br}_2$)); 356 (M (^{81}Br , ^{79}Br)); 354 (M ($^{79}\text{Br}_2$)); 316, 314, 312, 283, 281, 279, 277, 275, 235, 233, 200, 172, 153, 143.

EXAMPLE 6

4-Bromo-5-(bromomethylene)-3-(1-acetamidobutyl)-2(5H)-furanone

Trimethylsilyl trifluoromethanesulfonate (0.1 ml) was added with stirring to a cooled solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.12 g, 0.37 mmol) in acetonitrile (10 ml) at -5°C. After stirring the reaction mixture at room temperature for 1h, it was quenched with water (20 ml) and extracted with ether (3 x 40 ml). The combined ether extracts was washed with brine, dried over sodium sulfate and evaporated to yield the amide as a light tan oil (0.1g, 74%).

Recrystallisation of the crude product from dichloromethane/light petroleum gave the pure amide as yellow powder, m.p. 153-55°C ^1H n.m.r. δ (CDCl_3) 0.93, t, J 7.2 Hz, (H_4')₃; 1.24-1.40, m, (H_3')₂; 1.66-1.77, m, (H_2')₂; 1.98, s, NHCoCH_3 ; 5.02, q, 7.9 Hz, H_1' ; 6.25, bd, J 8.7 Hz, NH ; 6.38, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.5, C_4' ; 19.0, C_3' ; 23.1, NHCoCH_3 ; 35.2, C_2' ; 45.7, C_1' ; 93.6, 5-CHBr; 130.9, C_4 ; 131.9, C_3 ; 149.6, C_5 ; 165.3, C_2 ; 169.6, NHCO . Mass spectrum: m/z 369, (M ($^{81}\text{Br}_2$), <5%); 367 (M (^{81}Br , ^{79}Br), <5); 365, (M ($^{79}\text{Br}_2$), <5); 362 (5); 364 (5); 326 (18); 324 (30); 322 (18); 284 (28); 282 (53); 280 (30).

EXAMPLE 7

5-(Dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone

A solution of 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (18.0 g, 0.05 mol) in a mixture of dioxane (200 ml) and sulfuric acid (3M, 35 ml) was refluxed in an oil bath for 3h. After cooling the mixture to room temperature, it was diluted with water (300 ml) and extracted with dichloromethane (3 x 200 ml). The combined dichloromethane extracts were washed with water, dried and evaporated. The crude product was purified by silica gel chromatography using dichloromethane / light petroleum (1 : 1) as an eluent to yield the hydroxyethyl furanone (9.6 g, 62%) as a white solid. m.p. 100°C. ν_{\max} 3300, 2870, 1750, 1595, 1440, 1370, 1250, 1170, 1030, 985,

955, 835, 770, 720 cm^{-1} . λ_{max} 311 nm (ϵ 5832). ^1H n.m.r. δ (CDCl_3) 1.50, d, J 7.2 Hz, (H_2')₃; 4.72, m, 1H, H_1' ; 7.49, bs, H₄. ^{13}C n.m.r. δ (CDCl_3): 21.8, C2'; 63.4, C1'; 81.3, 5-CHBr; 133.7, C₄; 140.3, C₃; 149.5, C₅; 167.3, C₂. Mass spectrum: m/z 300, ($\text{M}+1$ ($^{81}\text{Br}_2$), 18%); 298 ($\text{M}+1$ (^{81}Br , ^{79}Br), 36); 296, ($\text{M}+1$ ($^{79}\text{Br}_2$), 18); 285 (22); 283 (41); 281 (28); 257 (78); 255 (100); 253 (78); 219 (15); 217 (15); 201 (22); 200 (34); 199 (36); 174 (24); 172 (38); 170 (18); 147 (21); 145 (28); 119 (38); 117 (38).

EXAMPLE 8

5-(Dibromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone

The procedure described for 5-(dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone was used to treat 3-(1-acetoxybutyl)-5-(dibromomethylene)-2(5H)-furanone (0.70g, 1.9 mmol) with sulfuric acid (3 M, 5 ml) in dioxane (30 ml) to give after chromatography the hydroxybutyl furanone as a yellow oil (0.42g, 68%) ν_{max} 3441, 2960, 2931, 2873, 1779, 1615, 1267, 1174, 1020, 965, 848 cm^{-1} . λ_{max} 303.6 nm (ϵ 1161). ^1H NMR d: 0.95 (t, 3H, H-4'); 1.43 (m, 2H, H-3'); 1.78 (m, 2H, H-2'); 3.22 (s, 1H, OH); 4.58 (d, 1H, H-1'); 7.52 (s, 1H, H₄). Mass spectrum: m/z 328 (M ($^{81}\text{Br}_2$)); 326 (M (^{81}Br , ^{79}Br)); 324 (M ($^{79}\text{Br}_2$)); 299; 297; 285; 283 (100%); 281; 257; 255; 253; 247; 245; 203; 205; 175; 173.

EXAMPLE 9

5-(Dibromomethylene)-3-(1-fluoroethyl)-2(5H)-furanone

A cooled solution of 5-(dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone (0.47g, 1.6 mmol) in analytical grade dichloromethane (2 ml) was added dropwise with stirring to a solution of (diethylamino)sulfur trifluoride (1 ml) in dichloromethane (2 ml) held in a dry ice/acetone cooling bath. The progress of the reaction was monitored by thin layer chromatography. Upon completion of the reaction, the mixture was added dropwise to a conical flask containing water (100 ml). The product was extracted with dichloromethane (3 x 50 ml) and the organic layer was dried over anhydrous sodium sulfate. The crude product was chromatographed on a silica column using dichloromethane as the eluent. The fraction with R_f of 0.90 in dichloromethane was collected and evaporated to yield the fluoro compound (0.47g, 97%) as a yellow solid m.p. 41°C. ν_{max} 3096, 2924, 2854, 1790, 1754, 1609, 1463, 1376, 1264, 1192, 1092, 990, 847, 771 cm^{-1} . λ_{max} 306.4 nm (ϵ 4269). ^1H NMR d: 1.62(m, 3H, H-2'); 5.34, 5.52(m, 1H, H-1'(CHF)); 7.58(s, 1H, 5-CHBr). ^{13}C n.m.r. δ (CDCl_3): 19.7 and 19.8, C2'; 82.3, CBr₂; 83.4 and

85.6, C1': 134.4, C4; 136.5 and 138.5, C3; 149.2, C5; 165.7, CO. Mass spectrum: m/z 302 (M ($^{81}\text{Br}_2$); 300 (M(^{81}Br , ^{79}Br); 298 (M($^{79}\text{Br}_2$); 202; 200; 198; 175 (100%); 172; 170.

EXAMPLE 10

5-(Dibromomethylene)-3-(1-fluorobutyl)-2(5H)-furanone

The procedure described for 5-(dibromomethylene)-3-(1-fluoroethyl)-2(5H)-furanone was used to treat 5-(dibromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.24g, 0.74 mmol) with (diethylamino)sulfur trifluoride (1.0 ml) in dichloromethane (3 ml) to give after chromatography the fluorobutyl furanone as a pale yellow oil (0.23g, 97%) ν_{max} 3084, 2961, 2874, 1780, 1614, 1465, 1379, 1266, 1180, 1026, 966, 847, 784, 680 cm^{-1} . λ_{max} 308.6nm (e 24923). ^1H NMR d: 0.95 (t, 3H, H-4'); 1.52 (m, 2H, H-3'); 1.88 (m, 2H, H-2'); 5.2, 5.4 (m, 1H, H-1'(CHF)); 7.56 (s, 1H, 5-CHBr). ^{13}C n.m.r. δ (CDCl_3): 13.5, C4'; 17.8, C3'; 35.6 and 35.9, C2'; 82.1, 5-CBr $_2$; 86.5 and 88.8, C1'; 134.8, C4; 135.7 and 135.7 and 136.0, C3; 149.3, C5; 165.7 and 165.8, CO. Mass spectrum: m/z 330 (M ($^{81}\text{Br}_2$); 328 (M(^{81}Br , ^{79}Br); 326 (M($^{79}\text{Br}_2$); 288; 286; 284; 247 (100%); 207; 205.

EXAMPLE 11

4-Bromo-5-(bromomethylene)-3-(1-butanoyloxybutyl)-2(5H)-furanone

4-Bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (4.75 g, 0.015 mol) and butanoyl chloride (7.8 ml, 0.075 mol) were refluxed together for 7h then cooled and poured into water (50 ml) and extracted with ether (3 x 30 ml). The combined ether extracts were washed sequentially with saturated sodium bicarbonate (2 x 50 ml) and brine (50 ml), dried over sodium sulfate, and evaporated. The crude product was purified by silica gel chromatography using ether / light petroleum (1 : 9) as the eluent to yield the butanoyloxybutyl furanone as a pale yellow oil (3.60 g, 60%). ν_{max} 2950, 1780, 1730, 1635, 1600, 1450, 1380, 1280, 1240, 1165, 1060, 980, 840, 770 cm^{-1} . λ_{max} 289 nm (e 14900). ^1H n.m.r. δ (CDCl_3) 0.91, t, J 7.4 Hz, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 0.93, t, J 7.2 Hz, (H4') $_3$; 1.35, m, (H3') $_2$; 1.66, q, J 7.4 Hz, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 1.80-1.95, m, (H2') $_2$; 2.32, t, J 7.4 Hz, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 5.50, dd, J 6.4 Hz 8.0 Hz, H1'; 6.36, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.4, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 13.5, C4'; 18.2, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 18.4, C3'; 33.5, C2'; 35.7, $\text{OCOCH}_2\text{CH}_2\text{CH}_3$; 68.0, C1'; 93.2, 5-CHBr; 130.6, C4; 132.4, C3; 149.6, C5; 165.9, C2; 172.7, CO. Mass spectrum: m/z 399, (M+1 ($^{81}\text{Br}_2$), <5%); 397 (M+1 (^{81}Br , ^{79}Br), <5); 395, (M+1 ($^{79}\text{Br}_2$), <5); 327 (18); 325 (28); 323 (18);

317 (26); 315 (26); 311 (8); 309 (16); 307 (8); 283 (16); 281 (34); 279 (16); 267 (42); 265 (40); 247 (16); 245 (16); 223 (56); 221 (44).

EXAMPLE 12

4-Bromo-5-(bromomethylene)-3-(1-octadecanoyloxybutyl)-2(5H)-furanone

4-Bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.24 g, 0.7 mmol) and octadecanoyl chloride (0.3 ml, prepared from octadecanoic acid and thionyl chloride) were stirred in an oil bath at 110°C for 24 h. The reaction mixture was diluted with ether (50 ml) and washed with water (3 x 20 ml) followed by brine (30 ml). The organic phase was dried over sodium sulfate and evaporated to yield a brown oil. The crude product was purified by silica gel chromatography using dichloromethane as the eluent to yield the octadecanoyloxybutyl furanone as dark tan oil (0.14 g, 32%). ¹H n.m.r. δ (CDCl₃) 0.87, t, J 7.2 Hz, OCO(CH₂)₁₆CH₃; 0.95, t, J 7.2 Hz, (H_{4'})₃; 1.28, m, OCOCH₂(CH₂)₁₅CH₃; 1.35-1.45, m, (H_{3'})₂; 1.58-1.60, m, OCOCH₂CH₂; 1.75-2.05, m, (H_{2'})₂; 2.34, t, J 7.2 Hz, OCOCH₂(CH₂)₁₅CH₃; 5.43, dd, J 6.2 Hz 7.7 Hz, H_{1'}; 6.37, s, 5-CHBr. ¹³C n.m.r. δ (CDCl₃): 13.5, OCO(CH₂)₁₆CH₃; 14.1, C_{4'}; 18.6, 22.7, 24.8, 29.2, 29.3, 29.4, 29.6, 29.7, 31.9, 33.8, 33.9, CH₂; 68.0, C_{1'}; 93.3, 5-CHBr; 130.7, C₄; 131.3, C₃; 149.8, C₅; 163.7, C₂; 173.1, CO.

EXAMPLE 13

Method A

4-Bromo-5-(bromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone

The procedure described for 4-bromo-5-(bromomethylene)-3-(1-butanoyloxybutyl)-2(5H)-furanone was used to treat 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (4.75 g, 0.015 mol) with acryloyl chloride (6.0 ml, 0.073 mol). The crude product was purified by silica gel chromatography using ether / light petroleum (1 : 9) as the eluent to yield the acryloyloxybutyl furanone as a pale yellow oil (3.60 g, 60%). ν_{max} 3060, 2940, 2850, 1770, 1710, 1620, 1590, 1430, 1390, 1385, 1280, 1250, 1160, 1095, 1030, 970, 835, 795, 760, 700 cm⁻¹. λ_{max} 293 nm (ε 18170). ¹H n.m.r. δ (CDCl₃) 0.91, t, J 7.4 Hz, ester CH₃; 0.97, t, J 7.4 Hz, (H_{4'})₃; 1.38, m, (H_{3'})₂; 1.84-2.04, m, (H_{2'})₂; 5.63, dd, J 6.7 Hz 8.2 Hz, H_{1'}; 5.88, d, J 10.7 Hz, CH=CH₂; 6.14, dd, J 10.7 Hz 16.3 Hz, CH=CH₂; 6.39, s, 5-CHBr; 6.46, d, J 16.3 Hz, CH=CH₂. ¹³C n.m.r. δ (CDCl₃): 13.5, C_{4'}; 18.5, C_{3'}; 33.7, C_{2'}; 68.2, C_{1'}; 93.5, 5-CHBr; 127.5, CH=CH₂; 130.4, C₄; 131.5, CH=CH₂; 132.1, C₃; 149.8, C₅; 163.7, C₂; 165.2, CO. Mass spectrum: m/z 382, (M (⁸¹Br)₂, <5%); 380 (M (⁸¹Br, ⁷⁹Br), <5); 378, (M (⁷⁹Br)₂, <5); 327 (14); 325 (28); 323 (14);

301 (16); 299 (16); 283 (8); 281 (12); 279 (8); 269 (12); 267 (24); 265 (12); 229 (18); 227 (24); 225 (18); 223 (20); 203 (34); 201 (46); 175 (32); 173 (48); 147 (38); 145 (46); 143 (48).

Method B

Concentrated sulfuric acid (1 drop) was added to a solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.94 g, 3.0 mmol) and acrylic acid (2 ml) in benzene (5 ml). The mixture was refluxed for 4 h, and after cooling to room temperature, poured into water (50 ml). The crude product was extracted with ether (2 x 50 ml), and the combined ether extract washed with sodium carbonate solution. The extract was dried over anhydrous sodium sulfate, evaporated and chromatographed over silica column using dichloromethane/light petroleum as the eluent to yield the pure acryloyloxybutyl furanone as a tan oil (0.48 g, 42%).

EXAMPLE 14

4-Bromo-5-(bromomethylene)-3-(1-butanoyl)-2(5H)-furanone

To an ice cooled solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (2.77 g, 8.5 mmol) in acetone (75 ml) was added dropwise with stirring Jones reagent (12 ml, prepared by dissolving chromium trioxide (13.36 g) in sulfuric acid (11.2 ml) and water (38.5 ml). The mixture was stirred at room temperature for 1h and the progress of the reaction monitored by thin layer chromatography. After the completion of the reaction, the mixture was poured into water (200 ml) and extracted with ether (3 x 100 ml). The combined ether extracts were washed with brine (100 ml), dried over sodium sulfate and evaporated to yield the crude ketone (2.23g, 81%) as a yellow solid. Recrystallisation of the crude ketone from dichloromethane/hexane gave the pure ketone as yellow plates, m.p. 83-84°C ν_{\max} 1700, 1680, 1630, 1540, 1310, 1000 cm^{-1} . ^1H n.m.r. δ (CDCl_3) 0.97, t, J 7.2 Hz, (H_4')₃; 1.70, m, (H_3')₂; 2.93, t, J 7.2 Hz, (H_2')₂; 6.74, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.6, C4'; 16.7, C3'; 44.4, C2'; 99.3, 5-CHBr; 125.7, C4; 138.1, C3; 150.4, C5; 163.5, CO; 194.1, C1'. Mass spectrum: m/z 326, ($\text{M}^{(81}\text{Br})_2$, <5%); 324 ($\text{M}^{(81}\text{Br}, ^{79}\text{Br})$, 5); 320, ($\text{M}^{(79}\text{Br})_2$, <5); 298 (10); 296 (22); 281 (16); 279 (8); 225 (4); 131 (14); 77 (32); 71 (52), 43 (100).

Covalently Bound Furanone Polymer Synthesis

EXAMPLE 15

Preparation of furanone acrylate homopolymer

A mixture of 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone (0.36 g), AIBN (0.003 g) and toluene (0.75 ml) was degassed and then heated at 60°C for 24h. Hexane was added to the mixture and the precipitated polymer was washed once with methanol. The final product was collected and dried to yield the polymer (0.04 g, 11% conversion) of average mass 14284.

EXAMPLE 16

Preparation of furanone acrylate-polymethyl methacrylate copolymer

A mixture of methyl methacrylate (3.0 g), 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone (0.74 g) and AIBN (0.006 g) was degassed for 1/2h by purging with nitrogen gas and then heated at 60°C for 24h. Hexane (50 ml) was added to the mixture and the precipitated polymer was washed once with methanol. The polymer was further purified by reprecipitation from chloroform and excess methanol. The final product was collected and dried to yield the polymer (1.74 g, 47% conversion) of average mass.7578.

EXAMPLE 17

Preparation of furanone acrylate-polystyrene copolymer

A mixture of styrene (15 g), 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (0.16 g) and AIBN (0.023 g) was degassed for 1/2h by purging with nitrogen gas and then heated at 60°C for 3h. After the completion of polymerisation, the mixture was poured into hexane and the precipitated polymer was washed twice with ether and dried in vacuo (0.1 mm Hg) at 40°C for 24h to yield the polymer (12.9 g, 85% conversion). An XPS analysis of the powdered polymer in aluminium foil confirmed the presence of bromine.

EXAMPLE 18

Preparation of furanone acrylate-poly(Styrene/MEMA/MMA) polymer

To a solution of styrene (5 g), MMA (5 g) and HEMA (5 g) in toluene (8 ml) was added 4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (0.15 g) followed by dodecanethiol (2 ml) and AIBN (0.4 g). The mixture was degassed by two freeze-thaw cycles and then heated at 70°C for 24h. After the completion of polymerisation, the mixture was treated with hexane and the precipitated polymer was washed with hexane and dried in vacuo (0.1mm Hg) at room temperature for 24h to yield the polymer (22.2 g, 87% conversion).

EXAMPLE 19

4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone

Concentrated sulfuric acid (2 drops) was added to a solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (2.0 g) in toluene (10 ml). The mixture was refluxed for 4h, and after cooling to room temperature, poured into water (50 ml). The crude product was extracted with ether (2 x 50 ml), and combined ether extract washed with sodium carbonate solution. The extract was dried over sodium sulfate, evaporated and chromatographed over silica column using light petroleum as the eluent to yield the pure 3-(1-1-butenyl)-furanone as a light yellow oil (0.40 g). $^1\text{Hnmr}$ d (CCl_3) 1.10, t, J 7.2 H_2 , ($\text{H}4'$)₃; 2.26, q, J 7.2 H_2 , ($\text{H}3'$)₂; 6.20, d, $\text{CH}=\text{CH}$; 7.20, d, $\text{CH}=\text{CH}$, 6.24, s, 5-CHBr

Fimbrolide Biological Activity**MATERIALS AND METHODS****Inhibition of Cyprid Settlement**

The effects of synthetic furanones on the settlement of barnacle larvae were tested using cyprids of the cosmopolitan fouling barnacle *Balanus amphitrite* Darwin. The naturally occurring furanone 2, and the synthetically prepared compounds 281 (a 1:1:1 mixture of synthesised 2 & 8 & 1), 2223 (a 1:1 mixture of synthesised 22 & 23), 2425 (a 1:1 mixture of synthesised 24 & 25), 26, 27, and 28 (Figure 1) were compared for their efficacy in deterring barnacle cyprid settlement. Compounds were dissolved in ethanol (99.7% + purity) at a concentration of $180 \mu\text{g}.\text{ml}^{-1}$ to $1.8 \mu\text{g}.\text{ml}^{-1}$. A 0.5 ml aliquot of each compound to be tested was added to treatment petri dishes (surface area 9 cm^2), and 0.5 ml of ethanol only was added to ethanol control dishes. Dishes were dried on a shaker resulting in a coating of extract on treatment dishes with a concentration range of $10 \mu\text{g}.\text{cm}^{-2}$ to $100 \text{ ng}.\text{cm}^{-2}$ for each compound.

Cypris larvae were obtained from laboratory cultures of adult brood stock of *Balanus amphitrite*. Nauplii of *B. amphitrite* were collected and reared on *Skeletonema costatum* until reaching cyprid stage. Cypris larvae were filtered and maintained in filtered seawater at 5°C for five days prior to use in settlement assays (Rittschof *et al.*, 1992).

Settlement tests were conducted by adding 25-35 cyprids to either treatment dishes, ethanol control dishes, or untreated dishes, each containing 4 ml of sterilised filtered seawater ($0.22\ \mu\text{m}$). All the treatments and controls were tested in triplicate. Test dishes were incubated for 24 h at 28°C in a 15:9 h light-dark cycle (Rittschof *et al.*, 1992). After 24 h, the test was terminated by the addition of three drops of 40% formaldehyde, and non-settled larvae filtered from the dish. The percent settlement of cyprids was then determined by counting settled and non-settled larvae.

Statistical Analyses

The data from the bioassays were analysed by analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Data were analysed as percentages after arcsin \sqrt{x} transformations.

RESULTS

Inhibition of Cyprid Settlement

The settlement of *Balanus amphitrite* Cypris larvae was significantly inhibited by the compounds tested (Figure 2; two-factor ANOVA [metabolite x concentration] followed by Tukey's test). All treatments completely inhibited settlement at the highest concentration ($10\ \mu\text{g.cm}^{-2}$). Ethanol controls were used in the analysis as ethanol had no significant effect on settlement (single factor ANOVA, $P=0.17$). The synthetic furanone 2223 (Figure 1) was the most active metabolites (Figure 2). At a concentration of $1\ \mu\text{g.cm}^{-2}$ 2223 completely inhibited settlement and inhibited settlement by 80% compared to the control at $500\ \text{ng.cm}^{-2}$. The next most inhibitory compound was the furanone 28 (Figure 1) which inhibited settlement completely at $5\ \mu\text{g.cm}^{-2}$ and inhibited settlement by 90% at $1\ \mu\text{g.cm}^{-2}$. A group of furanones, 2425, 26 and 27 completely inhibited settlement at $5\ \mu\text{g.cm}^{-2}$ but had no effect at $1\ \mu\text{g.cm}^{-2}$. The furanone 2 and the synthetic analogue 281, a 1:1:1 mixture of 2, 8 and 1 (Figure 1) were the least effective compounds completely inhibiting settlement at $10\ \mu\text{g.cm}^{-2}$.

Inhibition of *Staphylococcus aureus*

Staphylococcus aureus is a facultatively anaerobic, nonmotile, gram-positive coccus and is normally associated with the skin, skin glands, and mucous membranes of humans. *S. aureus* is the most important human staphylococcal pathogen and causes, for example, boils, abscesses and wound infections.

A screening experiment of the different furanones against the growth of *S. aureus* was performed in a BioRad 3550 Microplate reader. The growth was measured as absorbance at 610 nm up to 9 h. A complex growth media, Nutrient Broth, was used and the cells were grown at 37°C. Both natural furanones (compounds 2, 3 and 4) and synthesised furanones (compounds 33/34 and 45) were used in the experiment at the concentration 10 µg/ml.

The results showed that the synthesised furanones (33/34 and 45) inhibited growth of *S. aureus* more effectively than the natural furanones (Figure 3). The growth of the cells inoculated with 33/34 and 45 was completely inhibited for 9 h compared to 2 h for those inoculated with the natural compounds. All furanones, however, inhibited the growth of *S. aureus* compared to the control.

Further experiments were performed with the synthesised furanones 45 and 33/34 at the concentrations 10 µg/ml and 5 µg/ml. The cells were grown in side arm flasks in NB media at 37°C. The growth of the cells were measured at 610 nm for up to 48 h.

The results showed that compound 33/34 was more effective at inhibiting growth of *S. aureus* compared to compound 45 (Figure 4), however, both compounds at both concentrations inhibited the growth completely for 9 h. Growth of the cells occurred after 9h with compound 45 at the concentration 5µg/ml and after 15 h at the concentration 10 µg/ml. Compound 33/34 at 5µg/ml inhibited the growth for 15 h and at the concentration 10 µg/ml the growth of *S. aureus* was completely inhibited for 34 h.


DISCUSSION

The derivatisation of naturally occurring furanones resulted in an increase in the deterrence of barnacle settlement. For example, manipulation of the length of the acyl side chain and the functionality on the 1' position of the acyl side chain of the furanone resulted in a significant increase in activity. This is clearly demonstrated in a comparison of the activity of furanones 2 and 2425. In 2425 a bromine has been added in the 1' position of acyl chain resulting in a five fold increase in activity in the settlement bioassay (Figure 2). All of the synthesised furanones are either novel compounds not being previously reported in the literature or are racemic mixtures of a naturally occurring furanone. The racemic analogues of the naturally occurring compounds have the same activity as the naturally

occurring optically pure form. Therefore, the synthetic furanones, both analogues of naturally occurring compounds and novel compounds, have activity comparable to or better than the compounds from which their structure was derived, e.g. furanone 2 vs 2425.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

1. A compound according to formula (I):



(I)

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH,

$OC(O)R_6$, = O, amine, azide, thiol, mercaptoalkyl, alkenyloxy,

mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl,

$SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and

R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl. provided that:

when R_6 is propyl, R_2 is Br, R_3 is H or Br and R_9 is Br, then Z is other than H, $OC(O)CH_3$ or OH;


when R_6 is propyl, R_2 is Br, R_3 is H and R_9 is I, then Z is other than $OC(O)CH_3$ or OH;

when R_6 is propyl, R_2 is Br, R_3 is H and R_9 is Cl, then Z is other than OH;

when R_6 is propyl, R_2 is H, R_3 and R_9 are Br, then Z is other than H; and

when R_6 is propyl, R_2 is Br, R_9 is Cl and Z is H, then R_3 is other than Cl.

2. A compound according to claim 1 of formula (Ia):



(Ia)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen, OH, OOH, OC(O)R₁ or =O;

R₂ and R₃ are independently or both hydrogen or halogen; and


R₉ is halogen, provided that:

when R₁ is propyl, R₂ is Br, R₃ is H or Br and R₉ is Br, then X is other than OC(O)CH₃ or OH;

when R₁ is propyl, R₂ is Br, R₃ is H and R₉ is I, then X is other than OC(O)CH₃ or OH;

when R₁ is propyl, R₂ is Br, R₃ is H, R₉ is Cl, then X is other than OH.

3. A compound according to claim 1 of formula (II):



(II)

wherein R₁ is hydrogen, unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl;

R₂ and R₃ are independently or both hydrogen or halogen;


R₉ is halogen; and

R₄ is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl,

alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, OC(O)R_1 , SC(O)R_1 , OS(O)R_1 , $\text{OS(O)}_2\text{R}_1$, NHC(O)R_1 , OC(O)NHR_1 , or $=\text{O}$, provided that:

- 5 when R_4 is propyl, R_2 is Br, R_3 is H or Br, and R_9 is Br, then R_1 is other than H, OC(O)CH_3 or OH;
- when R_4 is propyl, R_2 is Br, R_3 is H, R_9 is I, then R_1 is other than OC(O)CH_3 or OH;
- when R_4 is propyl, R_2 is Br, R_3 is H, R_9 is Cl, then R_1 is other than OH;
- when R_4 is propyl, R_2 is H, R_3 and R_9 are Br, then R_1 is other than H;
- 10 when R_4 is propyl, R_2 is Br, R_3 and R_9 are Cl, then R_1 is other than H.

4. A compound according to claim 1 of formula (III):



15



wherein R_2 and R_3 are independently or both hydrogen or halogen;
 R_5 is OH or the same as R_1 ;
 R_9 is halogen; and

20

R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

5. A compound according to claim 1 of formula (IV) or (V):

25




wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;

R_9 is halogen and

R_8 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .

6. A method for forming a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):



wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen ($X = F, Cl, Br$ or I), OH, OOH, $OC(O)R_1$ or $=O$;


R_2 and R_9 are independently or both hydrogen or halogen; and

R_9 is halogen.

7. A method according to claim 6 wherein the halogenating agent is selected from the group N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, bromine, cupric bromide, and phenyltrimethylammonium perbromide.

8. A method according to claim 6 wherein the oxygenating agent is selected from lead tetraacetate, Rose Bengal/oxygen gas, hydrogen peroxide/vanadium pentoxide, selenium dioxide, and 3-chloroperoxybenzoic acid.

9. A method for forming a fimbrolide derivative, the method including displacement and/or functionalisation of the halogen or oxygen substituent in the fimbrolide side chain by treating with a nucleophile or an electrophile to form compounds with formula (II):



(II)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen;


R₉ is halogen; and

R₄ is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, OC(O)R₁, SC(O)R₁, OS(O)R₁, OS(O)₂R₁, NHC(O)R₁, OC(O)NHR₁, or =O provided that when R₄ is propyl, R₂ is Br, R₃ and R₉ are Cl, then R₁ is other than H.

10. A method according to claim 9 wherein the nucleophile is selected from metal halides, water, organic metal carboxylate, organic alcohols, dimethyl sulfoxide, and organonitrile/acid catalyst, and silver triflate.

11. A method according to claim 9 wherein the electrophile is selected from organic acids, isocyanates, acid halides or active acylating agents such as carbonyl imidazoles or anhydrides (including activated hydrophilic PEG acids, PEG acid chlorides, PEG-oxycarbonylimidazoles and PEG-isocyanates) organic sulfonyl chlorides, and diethylaminosulfur trifluoride.

12. A method for forming a fimbrolide derivative the method including reacting an hydroxyl substituent in the fimbrolide side chain with an oxidising agent to form a compound in accordance with formula (III):



wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;


R_9 is halogen; and

R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

13. A method according to claim 12 wherein the oxidising agents is selected from the group consisting of acid dichromate reagents in any form which may be free or polymer supported, chromium trioxide, manganese dioxide, potassium permanganate, selenium dioxide, ceric ammonium nitrate, ruthenium tetroxide, and hot nitric acid.

14. A method according to claim 13 wherein the acid dichromate agent is selected from the group consisting of Jones reagent, pyridinium chlorochromate, pyridinium dichromate.

15. A method for forming a fimbrolide analogue derived from a compound of formula (III)





wherein R₂ and R₃ are independently or both hydrogen or halogen;
R₅ is OH or the same as R₁;

R₉ is halogen; and

R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl
whether unsubstituted or substituted, straight chain or branched chain,
hydrophobic, hydrophilic or fluorophilic,

the method including reacting an aldehyde or ketone substituent in the
fimbrolide side chain of the compound with an amine derivative to form a
compound with formula (IV) or (V):



wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen;


R₉ is halogen and

R₈ is OH, NHR₁, NHC(X)NH₂, NHC(X)NHR₁ (X=O, S, NR₁) or any R₁.

16. A method according to claim 15 wherein the amine derivative is selected from the group hydroxyl amine hydrochloride, alkyl and aryl hydrazines, alkyl or aryl amine optionally in the presence of a reducing agent.

17. A fimbrolide derivative produced by a method in accordance with any one of claims 6 to 16.

18. An oligomer or polymer formed by oligomerisation or polymerisation of a fimbrolide compound of the formula:



wherein R₉ is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both H or halogen;

R₉ is halogen;

Z is independently selected from the group R₆, halogen, OOH, OC(O)R₆, = O, amine, azide, thiol, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, SC(O)R₆, OS(O)R₆, OS(O)₂R₆, NHC(O)R₆ = NR₄ or NHR₄; and

R₄ is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl,

optionally with at least one other monomer.

19. A polymer according to claim 18 wherein the polymer is a homopolymer of the fimbrolide compound of claim 18.

20. A polymer according to claim 18 wherein the polymer is a copolymer of at least one fimbrolide compound in accordance with claim 18 and at least one other polymerisable monomers.


21. Use of a compound in accordance with any one of claims 1 to 5 or 17 as antimicrobial, antiseptic, microbacterial static and/or antifouling agent.

22. An antimicrobial, antiseptic and/or microbacterial static composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims 18 to 20.

23. An antifouling composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims 18 to 20.

24. A surface coating composition incorporating at least one compound according to any one of claims 1 to 5 or 17 or an oligomer or polymer according to any one of claims 18 to 20.

25. A compound of formula (VI):



(VI)

wherein R₁ is alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen; and
R₉ is halogen.

26. A compound according to claim 25 which is 4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone.




Figure 1

2 / 14




Figure 2


Growth curves of *Staphylococcus aureus* against different furanones

Figure 3

4 / 14




Figure 4




Compound	Structure
3 (d5)	
4 (d19)	
5 (d14)	

Figure 5






10 (d16)	
20	
21	
22	
23	

Figure 5A






24	
25	
26	
27	
28	

Figure 5B






29	
33	
34	
35	
36	

Figure 5C




Figure 5D




Figure 5E




Figure 5F





49	
50	DEDICO 5981 (CASTOR OIL) 
51	
52	

Figure 5G




Figure 5H

14 / 14




Figure 5I

SUBSTITUTE SHEET (Rule 26) (RO/AU)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 047763-50

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PRODUCTION OF FURANONES

the specification of which:

is attached hereto; or

was filed as United States application Serial No. _____ on _____ and was amended on _____ (if applicable); or

was filed as PCT international application Number PCT/AU99/00285 on April 16, 1999 and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Australia	PP2978	April 16, 1998	[X] Yes [] No
			[] Yes [] No
			[] Yes [] No
			[] Yes [] No

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 047763-501

I hereby claim the benefits under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.	U.S. FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and; insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:
(name and telephone number)

Elizabeth C. Weimar
202-467-7000

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 047763-5

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE
OR FIRST INVENTORH-00
Roger READRESIDENCE &
CITIZENSHIP7 Lenthall Street, Kesington, NSW 2033, AustraliaCOUNTRY OF
CITIZENSHIP

AUSTRALIAN

POST OFFICE ADDRESS

7 Lenthall Street, Kesington, NSW 2033, Australia

FIRST OR SOLE INVENTOR'S SIGNATURE

R. Read

DATE

25/1/01

FULL NAME OF
SECOND INVENTOR2-01
Naresh KUMARRESIDENCE &
CITIZENSHIP33 White Avenue, Maroubra, NSW 2035, AustraliaCOUNTRY OF
CITIZENSHIP

AUSTRALIAN

POST OFFICE ADDRESS

33 WHITE AVENUE, MAROUBRA, NSW 2035, AUSTRALIA

SECOND INVENTOR'S SIGNATURE

Naresh Kumar

DATE 22/01/01

FULL NAME OF THIRD
INVENTORRESIDENCE &
CITIZENSHIPCOUNTRY OF
CITIZENSHIP

POST OFFICE ADDRESS

THIRD INVENTOR'S SIGNATURE

DATE

Listing of Inventors Continued on attached page(s) [] Yes [X] No